Results 71 to 80 of about 2,479 (207)

Galcanezumab in episodic migraine: subgroup analyses of efficacy by high versus low frequency of migraine headaches in phase 3 studies (EVOLVE-1 & EVOLVE-2). [PDF]

, 2019
BACKGROUND: Patients with high-frequency episodic migraine (HFEM) have a greater disease burden than those with low-frequency episodic migraine (LFEM).
Day, Katie A., Lipsius, Sarah, Silberstein, Stephen D., Stauffer, Virginia L., Wilson, Maria-Carmen   +4 more
core   +1 more source

Chronic Migraine as a Primary Chronic Pain Syndrome and Recommended Prophylactic Therapeutic Options : A Literature Review [PDF]

, 2023
Chronic pain conditions have a high socio-economic impact and represent a burden for patients, and their management is a challenge for healthcare professionals.
Csáti Anett, Szok Délia, Tajti János, Vécsei László   +3 more
core   +1 more source

Delayed urticaria during treatment with anti‐CGRP monoclonal antibodies in migraine

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To characterize clinical presentation and management of urticaria associated with calcitonin gene‐related peptide (CGRP) ‐targeting monoclonal antibodies (mAbs) for migraine prophylaxis. Background CGRP‐targeting mAbs are effective in migraine prophylaxis, but have been associated with hypersensitivity reactions, including urticaria.
Christoph T. Berger, Federico Burguet Villena, Severin B. Vogt, Lukas Heydrich, Karin Hartmann, Athina Papadopoulou   +5 more
wiley   +1 more source

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO‐CGRP study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background CGRP has an important role in migraine pathophysiology through neuronal modulation
María Clara García‐Castillo, Álvaro Sierra‐Mencía, Edoardo Caronna, Daniel Toledo‐Alfocea, Alex Jaimes, Sarai Urtiaga, Javier Casas‐Limón, Albert Muñoz‐Vendrell, Sonia Santos‐Lasaosa, Valvanuz García Martín, Guillermo Martín Ávila, Marcos Polanco, Maria Dolores Villar‐Martínez, Cristina Trevino‐Peinado, Laura Rubio‐Flores, Antonio Sánchez‐Soblechero, Leonardo Portocarrero Sánchez, Elisa Luque‐Buzo, Alberto Lozano‐Ros, Ana Beatriz Gago‐Veiga, Javier Díaz‐De‐Terán, Andrea Recio García, Javiera Canales Rodríguez, Andrea Gómez García, Marta González Salaices, Sergio Campoy, Ane Mínguez‐Olaondo, Stefania Maniataki, Vicente González‐Quintanilla, Jesús Porta‐Etessam, María‐Luz Cuadrado, Ángel Luis Guerrero Peral, Patricia Pozo‐Rosich, Jaime Rodríguez‐Vico, Mariano Huerta‐Villanueva, Julio Pascual, Peter J. Goadsby, Alicia Gonzalez‐Martinez   +37 more
wiley   +1 more source

Monoclonal Antibodies against Calcitonin Gene-Related Peptide for Migraine Prophylaxis: A Systematic Review of Real-World Data

Cells, 2022
Objective: To perform a systematic review of real-world outcomes for anti-CGRP-mAbs. Methods: Following the PRISMA guidelines, we searched PubMed for real-world data of erenumab, galcanezumab, fremanezumab, or eptinezumab in patients with migraines ...
Antun R. Pavelic, Christian Wöber, Franz Riederer, Karin Zebenholzer   +3 more
doaj   +1 more source

Depression and treatment with anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies for migraine [PDF]

, 2023
Background and purpose: The aim was to evaluate the effect of anti-calcitonin gene related peptide (CGRP) (ligand or receptor) antibodies on depressive symptoms in subjects with migraine and to determine whether depressive symptoms predict treatment ...
de Boer, Irene, de Vries Lentsch, Simone, MaassenVanDenBrink, Antoinette, Terwindt, Gisela M., van der Arend, Britt W.H., van Zwet, Erik W.   +5 more
core   +3 more sources

Effectiveness of galcanezumab versus topiramate, amitriptyline, and other select traditional oral migraine preventives with evidence of efficacy: 3‐Month results from the TRIUMPH study

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To compare the 3‐month effectiveness of galcanezumab with select traditional oral migraine preventive (TOMP) medications recommended by scientific societies (TOMP efficacy subset) and with the most frequently used individual TOMP medications.
Shivang Joshi, Cristina Tassorelli, Manjit Matharu, Taoufik Alsaadi, Carlos Vallarino, Lars Viktrup, Maurice Vincent, Rebecca L. Robinson   +7 more
wiley   +1 more source

The Bulletin: Sidney Kimmel Medical College at Thomas Jefferson University, Volume 67, Issue 1, Winter 2018 [PDF]

, 2018
This issue includes: Dean\u27s Column Findings: Living Electrodes may change neurological device design Ch-ch-ch-changes: Jefferson\u27s realignment of departments and programs The Difference Alumni Make: A message from Elizabeth Dale A Fighting ...

core   +1 more source

Are anti-calcitonin gene-related peptide monoclonal antibodies effective in treating migraine aura? A pilot prospective observational cohort study [PDF]

, 2023
Background: About 15% to one third of migraineurs experience aura symptoms. Aura is a reversible focal neurological phenomenon involving visual, sensory, speech, and motor symptoms that usually precede migraine pain.
Braca, Simone, Cretella, Gennaro, De Simone, Roberto, Miele, Angelo, Russo, Cinzia Valeria, Stornaiuolo, Antonio   +5 more
core   +1 more source

A Comparison of Regional Decisions for Doses and Administrations of New Drugs: Concordance, Discordance, and Dependencies

Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1350-1361, May 2026.
Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley   +1 more source